A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.
Keep Reading
The upgraded CodeFusion Studio 2.0 simplifies how developers design, test and deploy AI on embedded systems.
Updated
January 8, 2026 6:34 PM
Illustration of CodeFusion Studio™ 2.0 showing AI, code and chip icons. PHOTO: ANALOG DEVICES, INC.
Analog Devices (ADI), a global semiconductor company, launched CodeFusion Studio™ 2.0 on November 3, 2025. The new version of its open-source development platform is designed to make it easier and faster for developers to build AI-powered embedded systems that run on ADI’s processors and microcontrollers.
“The next era of embedded intelligence requires removing friction from AI development”, said Rob Oshana, Senior Vice President of the Software and Digital Platforms group at ADI. “CodeFusion Studio 2.0 transforms the developer experience by unifying fragmented AI workflows into a seamless process, empowering developers to leverage the full potential of ADI's cutting-edge products with ease so they can focus on innovating and accelerating time to market”.
The upgraded platform introduces new tools for hardware abstraction, AI integration and automation. These help developers move more easily from early design to deployment.
CodeFusion Studio 2.0 enables complete AI workflows, allowing teams to use their own models and deploy them on everything from low-power edge devices to advanced digital signal processors (DSPs).
Built on Microsoft Visual Studio Code, the new CodeFusion Studio offers built-in checks for model compatibility, along with performance testing and optimization tools that help reduce development time. Building on these capabilities, a new modular framework based on Zephyr OS lets developers test and monitor how AI and machine learning models perform in real time. This gives clearer insight into how each part of a model behaves during operation and helps fine-tune performance across different hardware setups.
Additionally, the CodeFusion Studio System Planner has also been redesigned to handle more device types and complex, multi-core applications. With new built-in diagnostic and debugging features — like integrated memory analysis and visual error tracking — developers can now troubleshoot problems faster and keep their systems running more efficiently.
This launch marks a deeper pivot for ADI. Long known for high-precision analog chips and converters, the company is expanding its edge-AI and software capabilities to enable what it calls Physical Intelligence — systems that can perceive, reason, and act locally.
“Companies that deliver physically aware AI solutions are poised to transform industries and create new, industry-leading opportunities. That's why we're creating an ecosystem that enables developers to optimize, deploy and evaluate AI models seamlessly on ADI hardware, even without physical access to a board”, said Paul Golding, Vice President of Edge AI and Robotics at ADI. “CodeFusion Studio 2.0 is just one step we're taking to deliver Physical Intelligence to our customers, ultimately enabling them to create systems that perceive, reason and act locally, all within the constraints of real-world physics”.